ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2013
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.The Cochrane database of systematic reviews · 2020Pooled it
- 18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.Journal of Alzheimer's disease : JAD · 2018Pooled it
- The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.BMC medical imaging · 2024Article
- The impact of genetic risk for Alzheimer's disease on the structural brain networks of young adults.Frontiers in neuroscience · 2022Article
- Medial Temporal Atrophy Alone is Insufficient to Predict Underlying Alzheimer's Disease Pathology.Korean journal of family medicine · 2020Article
- Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.Journal of neurology · 2019Article
- Article
- Association of muscle and visceral adipose tissues with the probability of Alzheimer's disease in healthy subjects.Scientific reports · 2019Article
- Disrupted topology of the resting state structural connectome in middle-aged APOE ε4 carriers.NeuroImage · 2018Article
- Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer's Disease Using Clinical Research Center for Dementia of South Korea Data.Journal of clinical neurology (Seoul, Korea) · 2018Article
- FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.NeuroImage. Clinical · 2018Article
- Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer's Disease.Frontiers in neuroscience · 2018Article
- Controlled feature selection and compressive big data analytics: Applications to biomedical and health studies.PloS one · 2018Article
- Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model.Frontiers in human neuroscience · 2017Article
- Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.Alzheimer's research & therapy · 2016Article
- The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease.Journal of visualized experiments : JoVE · 2016Article
- Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?Alzheimer's & dementia (Amsterdam, Netherlands) · 2015Article
- A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.European journal of nuclear medicine and molecular imaging · 2015Review
- FDG-PET Contributions to the Pathophysiology of Memory Impairment.Neuropsychology review · 2015Review
- 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo capitalize on data from different clinical series to compare sensitivity and specificity of individual biomarkers for predicting mild cognitive impairment (MCI) progression to Alzheimer's disease (AD).
methodsMedial temporal atrophy, cortical hypometabolism, and cerebrospinal fluid biomarkers were assessed in 18 patients with mild cognitive impairment (MCI) with prodromal AD (pAD; conversion time, 26 ± 12 months) and 18 stable MCI (sMCI) patients from the Translational Outpatient Memory Clinic cohort, as well as in 24 pAD patients (conversion time, 36 ± 12 months) and 33 sMCI patients from the Alzheimer's Disease Neuroimaging Initiative cohort. Medial temporal atrophy was measured by manual, semi-automated, and automated hippocampal volumetry; cortical hypometabolism was measured using several indices of AD-related hypometabolism pattern; and cerebrospinal fluid markers were amyloid β (Aβ)42 and total tau protein concentrations. For each biomarker, sensitivity for pAD, specificity for sMCI, and diagnostic accuracy were computed.
resultsSensitivity to predict MCI conversion to AD in the Alzheimer's Disease Neuroimaging Initiative and Translational Outpatient Memory Clinic cohorts was 79% and 94% based on Aβ42, 46% and 28% based on hippocampal volumes, 33% to 66% and 56% to 78% based on different hypometabolism indices, and 46% and 61% based on total tau levels, respectively. Specificity to exclude sMCI was 27% and 50% based on Aβ42, 76% and 94% based on hippocampal volumes, 58% to 67% and 55% to 83% based on different hypometabolism indices, and 61% and 83% based on total tau levels, respectively.
conclusionsCurrent findings suggest that Aβ42 concentrations and hippocampal volumes may be used in combination to best identify pAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.